Pfizer Inc. today announced that it has completed the acquisition of GlaxoSmithKline’s quadrivalent meningococcalACWY vaccines Nimenrix and Mencevax. “The addition of Nimenrix and Mencevax help us to fulfill our vision to protect lives with innovative vaccines to fight serious diseases worldwide,” said Susan Silbermann, president and general manager, Pfizer Vaccines. “These vaccines addhigh-quality and complementary vaccines to our existing portfolio, allowing us to reach a broader global population.”
“With these two additions to the Pfizer Vaccine Portfolio, this will help us in fighting diseases better and ensuring that these Vaccines are helpful in protecting against meningococcal disease that can lead to disability and death. Meningococcal vaccination is mandatory for Hajj pilgrims and Mancevax has been the vaccine of choice in Pakistan for that purpose,” said Asim Sarfraz, Business Unit Lead for Vaccines at Pfizer Pakistan.
Pfizer Inc. has completed the global acquisition on October 1. In Pakistan, the two companies are working together to devise a plan for a smooth transition of these drugs.